Physician profile

Zakia Bowen

Internal Medicine · Newark, NJ

NPI 1982973731

$1,071.08

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$136.29

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $328.41 2019-2021
Bard Peripheral Vascular, INC. $161.34 2022
Smith+Nephew, INC. $120.29 2023 Collagenase Santyl
Boston Scientific Corporation $116.32 2019
E.R. Squibb & Sons, L.L.C. $101.73 2019-2023 Camzyos
Pfizer INC. $71.64 2019-2021
Novartis Pharmaceuticals Corporation $69.74 2019-2020
Astrazeneca Pharmaceuticals LP $52.92 2020-2021
Abbvie INC. $35.05 2021
Allergan, INC. $13.64 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Zakia Bowen

$1,071.08

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/2790163/zakia-bowen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.